Mini-Focus: High-Sensitivity TroponinValidation of High-Sensitivity Troponin I in a 2-Hour Diagnostic Strategy to Assess 30-Day Outcomes in Emergency Department Patients With Possible Acute Coronary Syndrome
Key Words
Abbreviations and Acronyms
Cited by (0)
Funded by Queensland Emergency Medicine Research Foundation, Christchurch Heart Institute and Health Research Council and Heart Foundation of New Zealand, Christchurch Emergency Care Foundation, Abbott Diagnostics, Alere, Swiss National Science Foundation, University Basel, Swiss Heart Foundation, Roche, Siemens, and University Hospital Basel. Dr. Cullen has received funding from the Queensland Emergency Medical Research Foundation for chest pain clinical trials; from Abbott Diagnostics, Roche, Alere, Siemens, and Radiometer Pacific for clinical trials; and from Alere, Boehringer-Ingelheim, Pfizer, AstraZeneca, Abbott Diagnostics, and Radiometer Pacific for speaking and education. Prof. Mueller has received research grants from the Swiss National Science Foundation, University Basel, Swiss Heart Foundation, Stiftung für kardiovaskuläre Forschung Basel, 8sense, Abbott, Alere, Brahms, Critical Diagnostics, Nanosphere, Roche, Siemens, and the Department of Internal Medicine; and honoraria to speak from Abbott, Alere, Brahms, Novartis, Roche, and Siemens. Dr. Parsonage has received funding from the Queensland Emergency Medicine Research Foundation, Abbott Diagnostics, Roche, Alere, and Beckmann Coulter for research on diagnostic protocols; and honoraria, travel expenses, and consultancy fees from Abbott, AstraZeneca, Hospira, and Sanofi-Aventis. Dr. Aldous has received funding from the National Heart Foundation (New Zealand) for cardiac research. Dr. Reichlin has received research grants from the Swiss National Science Foundation (PASMP3-136995), Swiss Heart Foundation, University of Basel, Professor Max Cloetta Foundation, and the Department of Internal Medicine, University Hospital Basel; and honoraria to speak from Brahms and Roche. Dr. Hammett has received consultancy fees from Lilly and Bayer; speaker fees from AstraZeneca, Lilly, Bayer, and Boehringer-Ingelheim; and travel grants from Abbott, AstraZeneca, Bayer, Boehringer-Ingelheim, Boston Scientific, Cordis, Lilly, Medtronic, Pfizer, Sanofi, and Schering-Plough. Dr. Ungerer has received funding from Pathology Queensland Study, Research and Education Trust Fund for unrelated research. Dr. Brown has received funding from AstraZeneca, Boehringer-Ingelheim, Aventis, and Roche to attend educational meetings; honoraria from Boehringer-Ingelheim and Roche for educational material; is on the Board of the Queensland Emergency Medical Research Foundation and received funding from this body as a co-investigator; and has been an Expert Medical Witness by the Queensland, Victorian, NT Coroner, and various legal companies. Peter George has received funding from Abbott, Beckman Coulter, and Roche for speaking. Dr. Flaws has received support from Alere to travel to meetings. Dr. Pemberton has received funding from the Health Research Council of New Zealand for studies investigating novel diagnostic markers of acute coronary syndromes. Dr. Richards has received speaker honoraria and funds from Roche Diagnostics and Alere for research support. Dr. Chu has received funding from the Queensland Emergency Medicine Research Foundation for unrelated research. Dr. Reid has received funding from the National Health & Medical Research Council (Australia) for Cardiovascular Research. Dr. Peacock has received research grants from Abbott, Alere, Brahms, Novartis, Roche, and The Medicines Company; has been a consultant for Abbott, Alere, Lily, and The Medicines Company; and has been a speaker for Bureau Abbott, and Alere. Dr. Deely has received funding from the Emergency Care Foundation for medical writing and Health Research Council (New Zealand) for unrelated research. Dr. Than has received funding from the Health Research Council (New Zealand) for two chest pain random clinical trials, the New Zealand National Heart Foundation for analysis of blood troponins from a chest pain clinical trial, and the Canterbury Community Trust for a diagnostic for unrelated research, and is Chair of the Emergency Care Foundation. All other authors have reported they have no relationships relevant to the contents of this paper to disclose.